
1. hum vaccin immunother. 2015;11(7):1573-84. doi: 10.1080/21645515.2015.1037058.

oncolytic viruses: bench bedside focus safety.

buijs pr(1), verhagen jh, van eijck ch, van den hoogen bg.

author information: 
(1)a department surgery; erasmus mc; university medical center ; rotterdam ,
the netherlands.

oncolytic viruses relatively new class anti-cancer immunotherapy agents.
several viruses undergone evaluation clinical trials last decades,
and first agent approved used novel cancer therapy 
modality. current review, overview presented recent (pre)clinical
developments field oncolytic viruses previously or
currently evaluated clinical trials. special attention given to
possible safety issues like toxicity, environmental shedding, mutation and
reversion wildtype virus.

doi: 10.1080/21645515.2015.1037058 
pmcid: pmc4514197
pmid: 25996182  [indexed medline]

